AstraZeneca to halt late-stage lung cancer trial of volrustomig

• The trial targeted patients with metastatic non-small cell lung cancer whose tumours do not express the PD-L1 protein, a specific biomarker subset
• The combination therapy failed to show promise for either progression-free survival or overall survival, the study's two primary effectiveness measures
• No new safety concerns were identified with volrustomig plus chemotherapy, though the discontinuation compounds worries about AstraZeneca's broader drug development pipeline

AstraZeneca Halts Late-Stage Lung Cancer Trial

Key Development:

AstraZeneca announced Monday, August 17, the discontinuation of a late-stage clinical trial testing volrustomig in combination with chemotherapy for metastatic non-small cell lung cancer (NSCLC).

Trial Details:

The decision followed recommendations from an independent data monitoring committee, which determined the volrustomig combination was unlikely to achieve either primary endpoint:

• Progression-free survival
• Overall survival

The trial specifically targeted patients with tumors lacking the PD-L1 protein.

Safety Profile:

AstraZeneca reported that the safety profile of volrustomig combined with chemotherapy remained consistent with known profiles of the individual medicines, with no new safety signals identified during the trial.

Market Implications:

This discontinuation contributes to a concerning pattern of setbacks for AstraZeneca in 2024, raising investor concerns about the strength and viability of the company's drug development pipeline. The halt represents another regulatory and commercial challenge for the pharmaceutical giant's oncology portfolio.

Company Impact:

The failure of this late-stage trial is particularly significant as it represents substantial prior investment in development and represents lost potential revenue from what could have been a treatment for a large patient population. Non-small cell lung cancer represents approximately 85% of all lung cancer cases, making it a major therapeutic area.

The news adds pressure on AstraZeneca to demonstrate success in other pipeline programs to maintain investor confidence and growth momentum in its oncology division.